R & d-other r & d-a RES/expl DEV

Ended Definitive Contract Awarded Last action

Contract number
00261200009D261005126
Awardee
Awarding agency
Obligated
$4,656,975

Award facts

Contract value 14% obligated
  • $18,461,968.00 Current, with exercised options
  • $32,129,968.00 Potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
Not on record
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer
Pricing
Cost No Fee
Place of performance
Houston, TX 77030, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action 7 · Phase II clinical trial of celecoxib in persons with genotype positive, phenotype negative FAP - WS #71 -$137,041
Other Administrative Action 6 -$457,109
Funding Only Action 5 $1,000,000
Supplemental Agreement for work within scope 4 $0
Supplemental Agreement for work within scope 3 $0
Supplemental Agreement for work within scope 1 $1,000,000
Original award $3,251,125

About this award

This is a research and development contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health, to the University of Texas MD Anderson Cancer Center (MD Anderson), a state-controlled higher education institution and comprehensive cancer treatment and research center. The $32,129,968.00 indefinite-delivery, indefinite-quantity (IDIQ) contract, awarded on September 26, 2000, supports the acquisition, testing, transportation, and housing of non-human primates for infectious disease and immunology studies at NIH facilities through June 30, 2007. The contract does not have a set-aside designation. As a prime contractor, MD Anderson has also received research grants and subcontracts from federal agencies such as the NCI, Department of Defense, and Department of Veterans Affairs to conduct a range of cancer research activities, including clinical trials, correlative studies, and infrastructure development.

Quick answers

Who was awarded contract 00261200009D261005126?

00261200009D261005126 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 26, 2000.

How much is contract 00261200009D261005126 worth?

The government has obligated $4,656,975 on 00261200009D261005126. Its current value, with exercised options, is $18,461,968. Its potential value, with all options, is $32,129,968.

Was contract 00261200009D261005126 competed?

The extent of competition for 00261200009D261005126 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award